Hypervision Surgical, a London-based developer of AI-powered hyperspectral imaging systems, has raised £17 million ($23M) in an oversubscribed Series A funding round led by Heal Capital. The capital will accelerate commercial deployment of its FDA-cleared HYPERSNAP® Surgical System and advance next-generation sensors with partner imec.
AI Surgical Imaging Draws Capital
The round comes amid rising investments in precision surgical tools, with SquareMind announcing $18M in funding the prior week for AI skin imaging. Hypervision's platform provides quantitative tissue insights using only safe light, differentiating it from fluorescence systems requiring contrast agents. Existing backers like ZEISS Ventures and redalpine rejoined, signaling conviction in hyperspectral technology's clinical potential.
Visibility Gaps Risk Surgical Outcomes
Surgeons rely on visual cues and contrast agents for tissue differentiation, but these methods limit precision in tumor resection and perfusion assessment. Up to 80% of cancer surgeries leave residual disease due to incomplete margins, per clinical challenges noted in research. Current fluorescence imaging adds risks like allergic reactions and costs. Hyperspectral imaging addresses this by revealing metabolic and oxygenation data invisible to the naked eye.
HYPERSNAP Delivers Real-Time Insights
HYPERSNAP® combines hyperspectral imaging with AI analytics for real-time, wide-field mapping of tissue oxygenation at over 60 frames per second. Unlike endoscopy-focused rivals like Diaspective Vision, it supports open and minimally invasive workflows without exogenous agents. The system earned FDA 510(k) clearance under a new AI/ML product code and UKCA marking.
As CEO Michael Ebner noted:
"Surgery has always been an act of vision, but it has been limited to what the human eye can see. We started Hypervision Surgical because we believed surgeons deserved to see more."
Heal Capital Bets on Surgical Intelligence
Heal Capital led the oversubscribed round, joined by Angelini Ventures, IP Group, Daycrest, and strategics like SAGES Ingenuity and Macmillan Cancer Support. New board additions include Tanja Dowe from Heal Capital and Rick Mangat, founder of NOVADAQ (acquired by Stryker). This mix of growth and strategic capital validates Hypervision's path from KCL spinout to U.S. market readiness. The £6.5M seed in 2023 brought total funding to over £23.5M.
Intraoperative Market Scales to $5B
The intraoperative imaging market stands at $3.67B in 2024, projected to reach $5.41B by 2030 at 6.8% CAGR. Within this, medical hyperspectral imaging grows from $2.9B in 2023 to $6.3B by 2030. Trends favor AI integration and contrast-free modalities, driven by precision oncology demands. Hypervision's on-chip advancements position it ahead of sensor providers like Headwall Photonics.
KCL Experts Drive Medtech Innovation
Co-founders include Professor Tom Vercauteren (CSO, KCL interventional imaging lead), CEO Michael Ebner (ex-Medtronic image fusion), and Sebastien Ourselin (Non-Exec Director, KCL Head of Biomedical Engineering, prior UCL spinout). Chairman Martin Frost founded and led CMR Surgical to unicorn status. Recent hires bolster regulatory and clinical translation from Ultromics and Cambridge Consultants. This academic-industry blend accelerates HYPERSNAP's OR integration.
US Commercialization Accelerates Post-FDA
Funds target U.S. commercial rollout, team expansion, and imec-co-developed next-gen hyperspectral sensors. Aggressive hiring in early 2026 supports scaling to 26 employees. Partnerships with NVIDIA for edge AI and selection for FDA's Safer Technologies Program de-risk expansion. Award wins like the IEEE Lippmann Award reinforce momentum toward broader surgical adoption.